A unicorn bags another $220M to fund its plans to upend the clinical trial process
The focus on decentralized trials amid the pandemic has led investors to make some big bets on companies promising to shake up the contract research space. Reify Health is the latest, coming away with $220 million to end what it calls the “sit and wait” period during trial enrollment.
“What we’re doing, and the future of clinical trials overall, goes beyond decentralized trials,” executive chairman Michael Lin said in a statement. “We need to have a global healthcare system proactively reaching out to patients everywhere and mobilizing the resources necessary to bring trials to them.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.